6th Jan 2016 14:05
LONDON (Alliance News) - Abzena PLC said Wednesday that NASDAQ-listed Gilead Sciences Inc had opted to stop its phase II study of simtuzumab in patients with idiopathic pulmonary fibrosis after a recommendation from the study's data monitoring committee.
The committee had recommended the data be terminated "due to a lack of efficacy." Simtuzumab is one of ten products created using Abzena's composite human antibody technology that is being clinically development by Abzena's partners.
Gilead is continuing its phase II study of the product in two other indications; patients with non-alcoholic steatohepatitis and primary sclerosing cholangitis, two liver diseases.
Shares in Abzena were down 2.4% at 60.50 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Abzena